Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

Discover how advances from various biotechs are bridging treatment gaps in menopause care, offering hope for managing ...

The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.

Risky but with rewards, Australian pharmaceutical companies developing treatments for rare diseases are competing for ...

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Vivek Ramaswamy, the biotech entrepreneur who competed for the Republican presidential nomination, hosted a town hall meeting ...

Creating a novel drug has always been a risky endeavor for biopharmaceutical companies. Developers and investors face ...

The United States leads the p-coumaric acid market, contributing over 30% of revenue. Driven by rising demand in the <a target=_blank href=https:/ ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

The rise in demand for collagen-based beauty and healthcare products continues to accelerate due to advancements in ...

WWD Beauty Inc has created a definitive index of the ecosystem with this, our inaugural Financial Power Player list. On it, ...